Zura Bio Ltd
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $42.1M | $24.4M | $44.0M | $23.7M | — |
| Operating expenses | $75.2M | $55.2M | $62.6M | $27.2M | — |
| Operating income | -$75.2M | -$55.2M | -$62.6M | -$27.2M | — |
| Pretax income | -$68.7M | -$52.4M | -$60.6M | -$27.3M | — |
| Income tax expense | — | $0 | $0 | — | — |
| Net income | -$68.7M | -$52.4M | -$60.4M | -$25.7M | — |
| Balance Sheet | |||||
| Cash and equivalents | $109.4M | $176.5M | $99.8M | $13,785 | $729,223 |
| Current assets | $112.3M | $178.7M | $100.8M | $1.8M | $1.2M |
| Total assets | $113.9M | $179.5M | $100.8M | $5.3M | $140.6M |
| Current liabilities | $12.4M | $19.5M | $20.3M | $14.8M | $272,292 |
| Total liabilities | $12.4M | $19.5M | $21.3M | $14.8M | $10.4M |
| Stockholders' equity | $101.5M | $146.8M | $59.3M | -$32.1M | -$9.2M |
| Cash Flow Statement | |||||
| Cash from operations | -$64.8M | -$28.1M | -$15.1M | -$1.2M | — |
| Depreciation and amortization | $49,000 | $9,000 | — | — | — |
| Stock-based compensation | $12.3M | $16.8M | $7.5M | $334,000 | — |
| Capital expenditure | $113,000 | $75,000 | — | — | — |
| Free cash flow | -$64.9M | -$28.2M | — | — | — |
Shares outstanding 95.0M · Free float 41.7%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.